2020
BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies
Mckean M, Bendell J, Petrylak D, Powles T, Sonpavde G, Dickson A, Dosunmu L, Hennessy M, Jeffrey P, Rigby M, West T. BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies. Annals Of Oncology 2020, 31: s500-s501. DOI: 10.1016/j.annonc.2020.08.713.Peer-Reviewed Original ResearchPhase I/II studyPreliminary clinical activityAdvanced malignanciesII studyClinical activityNectin-4PatientsMalignancyPharmacokinetics
2006
A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
DiPaola R, Plante M, Kaufman H, Petrylak D, Israeli R, Lattime E, Manson K, Schuetz T. A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer. Journal Of Translational Medicine 2006, 4: 1. PMID: 16390546, PMCID: PMC1360095, DOI: 10.1186/1479-5876-4-1.Peer-Reviewed Original ResearchProstate-specific antigenSerious adverse eventsAdverse eventsProstate cancerB7-1ICAM-1Co-stimulatory molecules B7-1Mean prostate-specific antigenRecombinant vaccinia virus vaccineAndrogen-independent prostate cancerFurther phase IIPreliminary clinical activityInjection site reactionsPhase I trialVaccinia virus vaccineCo-stimulatory moleculesIndependent prostate cancerFeasible therapeutic approachRecombinant fowlpox virusStable diseaseMetastatic diseaseProgressive diseaseI trialTherapeutic vaccinesSafety profile